$5 iphoenix Raspberry Pi 4 B (Model B) Case w/Fan and heatsinks Electronics Computers Accessories Computer Components iphoenix Raspberry Pi 4 Regular dealer B Model and Case Fan heatsinks w and,$5,B),Case,4,w/Fan,B,Raspberry,/Homorelaps739822.html,heatsinks,(Model,Electronics , Computers Accessories , Computer Components,Pi,iphoenix,laagvlieger.x24hr.com $5 iphoenix Raspberry Pi 4 B (Model B) Case w/Fan and heatsinks Electronics Computers Accessories Computer Components iphoenix Raspberry Pi 4 Regular dealer B Model and Case Fan heatsinks w and,$5,B),Case,4,w/Fan,B,Raspberry,/Homorelaps739822.html,heatsinks,(Model,Electronics , Computers Accessories , Computer Components,Pi,iphoenix,laagvlieger.x24hr.com

iphoenix Raspberry Selling Pi 4 Regular dealer B Model and Case Fan heatsinks w

iphoenix Raspberry Pi 4 B (Model B) Case w/Fan and heatsinks

$5

iphoenix Raspberry Pi 4 B (Model B) Case w/Fan and heatsinks

|||

Product description

Color:Black

We are pleased to announce that this case is COMPATIBLE with the Raspberry Pi 4 Model B released June 24, 2019 An elegant, high-end case for your Raspberry Pi that includes heatsinks and a Fan. Featuring a removable lid for easy access to all connections with allowance for cable routing with lid in place for a clean appearance. This case is not flimsy or brittle, unlike other cases, this case features a thick-walled design strong enough to be taken apart and put re-assembled many times without failure. Not suitable for the Model 3B/B+ boards or the original format Model B.

iphoenix Raspberry Pi 4 B (Model B) Case w/Fan and heatsinks

CURRENT ISSUE
September, 2021

No. 106 (9)

2020 Impact Factor: 9.941 Submission > Acceptance: 52 days
ARTICLES IN THREE SENTENCES
Article

Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma

This open-label, single-arm study investigated the long-term efficacy of tafasitamab plus lenalidomide in 81 patients with relapsed/refractory diffuse large B-cell lymphoma. The response rate was 57.5%, including complete responses in 40.0% of patients, and the median duration of response was 43.9 months. This treatment is a valuable option for patients not eligible for autologous stem-cell transplantation.

Johannes Duell et al.

Case Report

Clinical genomic profiling of novel grey zone lymphoma paired lesions with sequential central nervous system involvement in two adolescent patients

Grey zone lymphoma is a B-cell lymphoma, unclassifiable, with features intermediate between those of large B-cell lymphoma and classic Hodgkin lymphoma. The in-depth study of the two adolescent patients described in this case report expands the clinicopathological and genomic spectrum of this rare pediatric disease. Moreover, it provides information on their response to treatment.

Cagla Y. Benkli et al.

Article

CAMT-MPL: congenital amegakaryocytic thrombocytopenia caused by MPL mutations - heterogeneity of a monogenic disorder - a comprehensive analysis of 56 patients

The clinical picture of 56 patients with congenital amegakaryocytic thrombocytopenia due to MPL mutations was much more varied than previously thought. Twenty-five per cent of them had no signs of thrombocytopenia at birth, and 50% had non-hematologic defects. Pancytopenia developed in (nearly) all patients and hematopoietic stem-cell transplantation was effective in 87% of cases.

Manuela Germeshausen et al.

Article

Oxidative stress activates red cell adhesion to laminin in sickle cell disease

Sickle red blood cells exhibit abnormal adhesion to laminin mediated by Lu/BCAM protein at their surface. This study provides evidence of the involvement of oxidative stress in post-translational modifications of Lu/BCAM which impact the protein’s distribution and cis-interaction with glycophorin C at the cell surface activating its adhesive function in dense sickle red cells. The authors speculate that antioxidant drugs might attenuate this phenomenon.

Maria Alejandra Lizarralde-Iragorri et al.

TAKE ADVANTAGE FROM HAEMATOLOGICA